Upcoming IPOs
All IPOs

Goldline Pharmaceutical Limited IPO Review

BSE SMEListed

Pharmaceuticals · Listed on BSE · 12 May 2026 - 14 May 2026

Jagat JoshiJagat Joshi
October 31, 2026
Issue Size
12.00 Cr
Price Band
₹41.00 - ₹43.00
Lot Size
3000 Shares
Min Investment
₹2,58,000
GMP
₹15
Subscription
840.74x
₹6,615.76 Cr
IPO Timeline
IPO OpensDONE
12 May 2026
IPO ClosesDONE
14 May 2026
Basis of AllotmentDONE
15 May 2026
RefundsDONE
18 May 2026
Demat CreditDONE
18 May 2026
ListingDONE
19 May 2026

About Goldline Pharmaceutical Limited IPO

Goldline Pharmaceutical IPO open date is May 12, 2026 and the IPO will close on May 14, 2026. Goldline Pharmaceutical IPO is a Book build Issue. The company to raise around ₹11.61 crores via IPO that comprises fresh issue of ₹11.61 crores and offer for sale up to [.] equity shares with face value of ₹10 each.

Goldline Pharmaceutical IPO price band is ₹41 to ₹43 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Goldline Pharmaceutical IPO to list on BSE SME on May 19, 2026. The allotment of Goldline Pharmaceutical IPO date is May 15, 2026.

The company reported revenue of ₹28.06 crores in 2025 against ₹23.57 crores in 2024. The company reported profit of ₹2.83 crores in 2025 against profit of ₹1.81 crores in 2024. As per the financials the IPO investors should apply the IPO for a long term.

Advertisement
Back to IPO Details

IPO Recommendations

Consensus review from market research firms & brokerage analysts

0
analysts
0
Apply
0
May Apply
0
Neutral
0
Avoid

Goldline Pharmaceutical Limited Review

No broker reviews have been published for this IPO yet.

User Reviews

Community Sentiment
Votes submitted by verified retail investors
0
votes
0
Apply
0
May Apply
0
Neutral
0
Avoid

Add Your Review

What is your recommendation for this IPO?

Loading options…

How would you rate this IPO (1 to 5)?

3
Disclaimer:

The IPO reviews, and recommendations published on this page are provided by respective authors, brokers, analysts, and contributors. These views do not represent the views of IPO Watch, its management, or its staff.

IPO Watch does not guarantee about the information or recommendations provided by third-party contributors. Use this content for informational and educational purposes only.

Investors are advised to do their own research, check offer documents, and consult a qualified financial adviser before making investment decisions.

IPO Watch reserves the right to review, modify, or remove any content that does not meet the editorial guidelines.

Advertisement

Frequently Asked Questions (FAQ)

Comments0

Join the discussion

Please sign in to leave a comment or reply.

Sorted by